Health Care • Biotechnology: Pharmaceutical Preparations
$9.73 ▼ -0.03
(-0.31%)
MKT CAP: $643.9M • VOL: 3.20M
52W L $8 52W H $31
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$8
MEDIAN
$11
MEAN
$11
HIGH
$13
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BCAX TAPE
BCAX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $11.77 | $11.19 | 2025-02-14 | $8.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $12.26 | $11.48 | 2025-02-06 | $9.15 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $11.09 | $10.70 | 2025-01-29 | $9.34 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $9.92 | — | 2025-01-17 | $9.54 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $8.56 | $9.24 | 2025-01-09 | $8.66 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $11.58 | $10.12 | 2024-12-18 | $8.47 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $9.44 | $9.83 | 2024-12-04 | $9.05 | -4.3% | 48% | C |